TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY

Robyn A. M. Guymer; Caroline Markey; Ian McAllister; Mark Gillies; Alex Hunyor; Jennifer Arnold

TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY

Robyn A. M. Guymer, Caroline Markey, Ian McAllister, Mark Gillies, Alex Hunyor, Jennifer Arnold

Centre for Ophthalmology and Visual Science (affiliated with the Lions Eye Institute)

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Article number	P0401
Pages (from-to)	36-36
Number of pages	1
Journal	Clinical and Experimental Ophthalmology
Volume	46
Publication status	Published - Nov 2018

Cite this

Guymer, R. A. M., Markey, C., McAllister, I., Gillies, M., Hunyor, A., & Arnold, J. (2018). TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY. Clinical and Experimental Ophthalmology, 46, 36-36. Article P0401.

Guymer, Robyn A. M. ; Markey, Caroline ; McAllister, Ian et al. / TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN : 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY. In: Clinical and Experimental Ophthalmology. 2018 ; Vol. 46. pp. 36-36.

@article{97379c6990d84f63b767b660e72cd6ee,

title = "TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY",

author = "Guymer, {Robyn A. M.} and Caroline Markey and Ian McAllister and Mark Gillies and Alex Hunyor and Jennifer Arnold",

year = "2018",

month = nov,

language = "English",

volume = "46",

pages = "36--36",

journal = "Clinical and Experimental Ophthalmology",

issn = "1442-6404",

publisher = "John Wiley & Sons",

}

Guymer, RAM, Markey, C, McAllister, I, Gillies, M, Hunyor, A & Arnold, J 2018, 'TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY', Clinical and Experimental Ophthalmology, vol. 46, P0401, pp. 36-36.

TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY. / Guymer, Robyn A. M.; Markey, Caroline; McAllister, Ian et al.
In: Clinical and Experimental Ophthalmology, Vol. 46, P0401, 11.2018, p. 36-36.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN

T2 - 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY

AU - Guymer, Robyn A. M.

AU - Markey, Caroline

AU - McAllister, Ian

AU - Gillies, Mark

AU - Hunyor, Alex

AU - Arnold, Jennifer

PY - 2018/11

Y1 - 2018/11

M3 - Abstract/Meeting Abstract

SN - 1442-6404

VL - 46

SP - 36

EP - 36

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

M1 - P0401

ER -

Guymer RAM, Markey C, McAllister I, Gillies M, Hunyor A, Arnold J. TOLERATING A DEGREE OF SUBRETINAL FLUID IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WITH RANIBIZUMAB USING A TREAT AND EXTEND REGIMEN: 24 MONTH RESULTS FROM THE PHASE IV, RANDOMISED, SINGLE-MASKED, MULTI-CENTRE FLUID STUDY. Clinical and Experimental Ophthalmology. 2018 Nov;46:36-36. P0401.